MedTrace Logo

Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin

NCT04414137 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-11-09

No results posted yet for this study

Summary

Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria.

Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide.

The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future

Conditions

  • Dactinomycin Adverse Reaction
  • Bone and Joint Infection

Interventions

OTHER

Description of eosinophilic pneumonia due to daptomycine

Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-19
Primary Completion
2021-01-20
Completion
2021-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04414137 on ClinicalTrials.gov